Cytokinetics Inc (CYTK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytokinetics Inc (CYTK) has a cash flow conversion efficiency ratio of 0.176x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-145.46 Million) by net assets ($-826.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cytokinetics Inc net asset quality index to measure how much of total assets are equity-financed.
Cytokinetics Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Cytokinetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Cytokinetics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Cytokinetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytokinetics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nova Ltd
TA:NVMI
|
0.050x |
|
Wynn Resorts Limited
NASDAQ:WYNN
|
-0.464x |
|
Eastroc Beverage Group Co Ltd
SHG:605499
|
0.071x |
|
Ivanhoe Mines Ltd.
TO:IVN
|
-0.006x |
|
FSN E-Commerce Ventures Limited
NSE:NYKAA
|
0.086x |
|
TMX Group Limited
TO:X
|
0.114x |
|
Accor S. A.
PA:AC
|
0.123x |
|
Symrise AG
F:SY1
|
0.019x |
Annual Cash Flow Conversion Efficiency for Cytokinetics Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Cytokinetics Inc from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see Cytokinetics Inc (CYTK) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-659.62 Million | $-510.01 Million | 0.773x | -73.56% |
| 2024-12-31 | $-135.37 Million | $-395.89 Million | 2.924x | +172.68% |
| 2023-12-31 | $-386.32 Million | $-414.33 Million | 1.073x | -61.36% |
| 2022-12-31 | $-107.90 Million | $-299.52 Million | 2.776x | +574.97% |
| 2021-12-31 | $243.86 Million | $-142.52 Million | -0.584x | -840.97% |
| 2020-12-31 | $113.38 Million | $8.94 Million | 0.079x | -99.05% |
| 2019-12-31 | $-10.94 Million | $-90.91 Million | 8.312x | +312.97% |
| 2018-12-31 | $25.93 Million | $-101.22 Million | -3.903x | -321.28% |
| 2017-12-31 | $109.84 Million | $-101.76 Million | -0.926x | -336.38% |
| 2016-12-31 | $94.36 Million | $36.98 Million | 0.392x | +450.52% |
| 2015-12-31 | $68.59 Million | $4.88 Million | 0.071x | +114.62% |
| 2014-12-31 | $92.06 Million | $-44.84 Million | -0.487x | -243.58% |
| 2013-12-31 | $54.44 Million | $-7.72 Million | -0.142x | +69.71% |
| 2012-12-31 | $71.44 Million | $-33.44 Million | -0.468x | +50.54% |
| 2011-12-31 | $48.18 Million | $-45.59 Million | -0.946x | -48.86% |
| 2010-12-31 | $70.52 Million | $-44.83 Million | -0.636x | -866.19% |
| 2009-12-31 | $101.43 Million | $8.42 Million | 0.083x | +106.73% |
| 2008-12-31 | $49.77 Million | $-61.33 Million | -1.232x | -3997.48% |
| 2007-12-31 | $99.92 Million | $-3.00 Million | -0.030x | +93.22% |
| 2006-12-31 | $106.31 Million | $-47.17 Million | -0.444x | +17.34% |
| 2005-12-31 | $73.56 Million | $-39.48 Million | -0.537x | -69.64% |
| 2004-12-31 | $107.56 Million | $-34.03 Million | -0.316x | -195.43% |
| 2003-12-31 | $-92.03 Million | $-30.51 Million | 0.332x | -9.93% |
| 2002-12-31 | $-60.59 Million | $-22.30 Million | 0.368x | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more